A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

NCT01483599 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

293

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: CNTO 1959 (5 mg)
DRUG: CNTO 1959 (15 mg)
DRUG: CNTO 1959 (50 mg)
DRUG: CNTO 1959 (100 mg)
DRUG: CNTO 1959 (200 mg)
DRUG: Adalimumab
DRUG: Placebo

Sponsor

Janssen Inc.